Cerebroprotein Hydrolysate Injection

Animal experiments have confirmed that the drug can accelerate the development of the chicken's brain. It is inferred that this product is beneficial to the protein synthesis of nerve cells and their respiratory chain, and at the same time stimulates the production of related hormones. Experiments also show that this product can effectively protect the central nervous system from toxic substances. Prior injection of this product can improve the rat's ability to resist hypoxia. These effects depend on the concentration of nucleic acids in the brain. After medication, the electro-optical mean proved that the brain maturation of rats of several days old was significantly accelerated, and the recognition ability of adult rats in the maze test was also enhanced. Compared with the control group, the glucose turnover rate in the blood-brain barrier of rats in the brain protein hydrolysate injection group was significantly accelerated. Toxicology: Safety pharmacology standardization studies have shown that human use of this drug will not cause chronic toxicity, reproductive toxicity, mutagenicity and carcinogenicity.

This product is a polypeptide preparation made by enzymatic hydrolysis of pig brain protein. The solution used for injection or drip does not contain protein, fat and other antigenic substances. Each milliliter of this product contains 215.2 mg of pig brain protein hydrolyzate.

This product is orange-yellow clear liquid.

-Primary dementia (such as Alzheimer's type senile dementia). -Vascular dementia (such as multi-infarct dementia, etc.) and cognitive dysfunction after mild or moderate stroke. -Mixed dementia. -Improvement of brain dysfunction after craniocerebral injury.

The recommended course of dosage is daily administration for a total of 10-20 days. It is best to have continuous injections for each course of treatment. Refer to the patient's age and condition to determine the length of the course and dosage. Subcutaneous injection should not exceed 2ml, intramuscular injection should not exceed 5ml, and intravenous injection should not exceed 10ml. In addition, it is recommended to use 10-30ml of this product diluted in 250ml of normal saline for slow dripping, which will take about 60-120 minutes to complete. Each course of treatment uses 10-20 drug drips, depending on the condition. In severe cases, especially those with cerebrovascular insufficiency, 10-30ml of this product can be diluted in 250ml of normal saline for dripping. If the drug is administered daily, 10-20 drug drips are used per course of treatment. This drug can be used with dextran (such as dextran 4

The stimulant activity of this preparation is occasionally accompanied by certain stimulant effects (excessive behavior, tension, insomnia). Very few patients have experienced hyperventilation, hypertension, hypotension, fatigue, tremor, depression, apathy, numbness, and cold-like symptoms (chills, cough, respiratory tract infection). A major adverse reaction associated with this product is a report of convulsions in one patient. Very few patients have experienced gastrointestinal reactions (poor appetite, indigestion, diarrhea, constipation, vomiting, nausea). When administering the drug by injection, if the injection is too fast, it may cause moderate fever or sweating, dizziness, and some patients may experience palpitations or arrhythmias. A small number of patients have reported local reactions to the drug, such as local skin redness, itching and

Hypersensitivity to any of the ingredients of this medicine. Epileptic status. Grand mal seizure: Taking this medicine at this time may increase the frequency of seizures. Severe renal insufficiency.

Based on the pharmacological characteristics of this product, special attention should be paid to the fact that the combined use of this drug with antidepressants or MAO-inhibitors may increase the effects of these drugs. In this case, it is recommended to reduce the dose of antidepressants. This drug should not be mixed with balanced amino acid solutions for infusion.

Protect from light, store at room temperature not exceeding 25°C, and do not freeze. Quickly extract the solution from the ampoule before use.

5ml

Shanghai Huayuan Pharmaceutical (Ningxia) Shasai Pharmaceutical Co., Ltd.

• Founded in:

  1994-07-29

• Address:

  No. 6 Road, High-tech Development Zone, Yinchuan City, Ningxia

• Tax NO.:

  91641100227756822X

• Registered Funds:

  13.6 million yuan

• Email:

  Log in to view